Survodutide 10mg Peptide
Research Use Only
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Survodutide is weighted toward the glucagon receptor more heavily than most dual agonists, and that balance is the reason its development has concentrated on liver endpoints as much as on weight. Glucagon receptor activation in hepatocytes drives lipid oxidation directly, which is a different route to hepatic fat reduction than the indirect one that comes from weight loss alone. Comparing it with mazdutide, which shares the same receptor pair from a different scaffold, is a common experimental design. This 10mg vial supports receptor-binding and comparative in vitro work.
Frequently Bought Together
Survodutide 10mg
10mg
$69 USD
Bundle & Save
$169 USD
Save $9 USD
$234 USD
Save $24 USD
$279 USD
Save $44 USD
$379 USD
Save $74 USD
Click any product above to toggle selection
Related Peptides
Related Research News
Survodutide Shows Renal and Metabolic Gains in DKD Mouse Model at ECO 2026
Researchers presented data at the European Congress on Obesity (ECO) on survodutide's effects in a mouse model of advanced diabetic kidney disease (DKD). The drug improved kidney injury markers like albuminuria and glomerulosclerosis, along with metabolic measures such as body weight and glucose levels. These results suggest potential for broader applications if confirmed in human studies.
Semaglutide Conference Presentation Preview: ObesityWeek 2026
ObesityWeek 2026 is set to feature key semaglutide conference presentations alongside emerging peptide therapeutics. Early reports suggest data on tirzepatide, retatrutide, survodutide, and cagrilintide will be shared, offering researchers a comprehensive look at the evolving obesity treatment landscape.
Daily Pill Could Tackle Dreaded Ozempic Rebound
A daily pill could serve as the answer to the dreaded Ozempic rebound. Retatrutide and survodutide appear in this context within clinical trials. This approach targets a common challenge after Ozempic treatment.